Breaking news from “The Pink Sheet” DAILY
Executive Summary
Visit 1www.ThePinkSheetDAILY.com for coverage of the latest developments in the pharmaceutical industry, including the FDA Antiviral Drugs Advisory Committee's approval recommendation for Bristol's Baraclude (entecavir) for treatment of chronic hepatitis B infection and a Crestor "untitled" letter. To sign up for a free trial of "The Pink Sheet" DAILY, visit our website or call customer service at 800-332-2181...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.